Trident Texofab Ltd

Trident Texofab Ltd has announced the forfeiture of 9,11,479 fully convertible warrants, representing 25% of the upfront consideration paid by certain warrant holders. These warrants, originally allotted on December 23, 2024, with an exercise price of ₹70 each, lapsed as the holders failed to exercise their option to convert them into equity shares within the stipulated 18-month period, which ended on June 22, 2026. The forfeited amount totals ₹1,59,50,882.50. Consequently, all outstanding warrants have lapsed and stand cancelled. The company stated that this action has not resulted in any change to its issued, subscribed, or paid-up equity share capital.

Trident Texofab Ltd announced the forfeiture of 9,11,479 fully convertible warrants during its Board Meeting on July 2, 2026. These warrants, originally allotted on December 23, 2024, were issued on a preferential basis to non-promoter public category investors at an issue price of ₹70 per warrant. The forfeiture occurred because the warrant holders failed to exercise their option to convert the warrants into equity shares within the stipulated 18-month period, which ended on June 22, 2026. Consequently, the upfront subscription amount paid for these warrants, totaling ₹1,59,50,882.50 (25% of the issue price), has been forfeited by the company. The company stated that this action has no impact on its issued, subscribed, or paid-up equity share capital.

Trident Texofab Ltd has announced the closure of its trading window for dealing in the company's securities, effective July 01, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will reopen 48 hours after the conclusion of the Board of Directors' meeting, which is scheduled to approve the Un-Audited Standalone Financial Results for the quarter ended June 30, 2026. The exact date of the board meeting will be communicated separately. This measure is standard practice to prevent potential insider trading ahead of financial result announcements.

Trident Texofab Ltd. has announced its audited standalone financial results for the year ended March 31, 2026. The Board of Directors approved the results at a meeting held on May 30, 2026. The statutory auditors, Shah Kailash & Associates LLP, issued an audit report with an unmodified opinion on the financial results. The company will publish an extract of the financial results in newspapers and on its website, as per SEBI Listing Regulations.

Trident Texofab Ltd's Board of Directors approved the audited standalone financial results for the year ended March 31, 2026, in compliance with SEBI regulations. The audit report, issued by Shah Kailash & Associates LLP, Chartered Accountants, contained an unmodified opinion. The board also reviewed compliances and updated the policy on Related Party Transactions.

Trident Texofab Ltd's Board Meeting, originally scheduled for May 28, 2026, to consider and approve the Audited Standalone Financial Results for the quarter and year ended March 31, 2026, has been adjourned. The adjournment occurred because the Audit Committee did not approve the financial results due to delays in preparation of the financial statements. The Audit Committee meeting is now adjourned until May 30, 2026. Consequently, the Board Meeting has also been rescheduled to Saturday, May 30, 2026, to consider and approve the same financial results. The company also confirmed that the trading window for designated persons remains closed until 48 hours after the results are made public on the revised date.

Trident Texofab Ltd has scheduled a meeting of its Board of Directors on May 28, 2026, to consider and approve the audited standalone financial results for the quarter and financial year ended March 31, 2026. The trading window for the company's equity shares has been closed since April 01, 2026, and will reopen 48 hours after the results are made public.

Trident Texofab Ltd responded to BSE's inquiry regarding significant movement in its share price. The company stated that all material information and announcements, including disclosures under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and insider trading regulations, have been disclosed within the stipulated time. Trident Texofab confirmed that there is no pending information or announcement that could have a bearing on the company's share price movement. The company attributed the share price fluctuations purely to market conditions, over which it has no control or specific knowledge of the reasons.

Trident Texofab Ltd. has announced the closure of its trading window pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be closed from April 01, 2026, and will be reopened 48 hours after the conclusion of the Board Meeting for the declaration of Audited Standalone Financial Results for the Quarter and year ended March 31, 2026. Directors, designated persons, their immediate relatives, and connected persons are not allowed to trade in securities of the company during this period.

Trident Texofab Ltd, in accordance with Schedule IV of the Companies Act, 2013 and Regulation 25(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, held a separate meeting of the independent directors on March 27, 2026. The meeting, held at 2004, 2nd Floor, North Extension, Falsawadi, Begumpura, Nodh 4/l65},Sahara Darwaja, Surat-395003, Gujarat, reviewed the performance of non-independent directors, the board as a whole, and the Chairman of the Company. The independent directors also assessed the quality, quantity, and timeliness of the flow of information between the Company's management and the Board.